{"id":"NCT04966741","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity","officialTitle":"A Phase 3 Multi-Center, 1-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 to <6 Years of Age With Rare Genetic Causes of Obesity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-08","primaryCompletion":"2023-09-18","completion":"2024-11-08","firstPosted":"2021-07-19","resultsPosted":"2024-07-10","lastUpdate":"2024-11-27"},"enrollment":12,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bardet-Biedl Syndrome","POMC Deficiency Obesity","PCSK1 Deficiency Obesity","LEPR Deficiency Obesity"],"interventions":[{"type":"DRUG","name":"Setmelanotide","otherNames":["IMCIVREE"]}],"arms":[{"label":"Setmelanotide: PPL Group","type":"EXPERIMENTAL"},{"label":"Setmelanotide: BBS Group","type":"EXPERIMENTAL"}],"summary":"This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \\<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) genes or Bardet-Biedl Syndrome (BBS).","primaryOutcome":{"measure":"Percentage of Participants With Greater Than or Equal to (â‰¥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52","timeFrame":"Baseline up to Week 52","effectByArm":[{"arm":"Setmelanotide: PPL Group","deltaMin":85.7,"sd":null},{"arm":"Setmelanotide: BBS Group","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States","Australia","Spain","United Kingdom"]},"refs":{"pmids":["39549719"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Skin hyperpigmentation","Vomiting","Nasopharyngitis","Upper respiratory tract infection","Injection site bruising"]}}